Dietary management remains foundational (~US $2.4 B in 2023), followed by pharmaceuticals (~US $2.0 B) and supplements (~US $1.74 B), highlighting broad strategy use https://www.datamintelligence.com/research-report/gluten-intolerance-treatment-market